East Ocyon Bio
Bangalore, India· Est.
Indian biotech delivering off‑the‑shelf CAR‑NK cell therapies for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Indian biotech delivering off‑the‑shelf CAR‑NK cell therapies for oncology and immunology.
OncologyImmunology
Technology Platform
CAR‑NK cell therapy platform enabling off‑the‑shelf NK cells engineered to target tumor antigens via non‑viral gene editing.
Opportunities
Growing demand for off‑the‑shelf cell therapies and expanding oncology market in India and globally.
Risk Factors
Technical challenges in NK cell manufacturing, regulatory hurdles, and competition from established CAR‑T and CAR‑NK players.
Competitive Landscape
Competes with firms like Fate Therapeutics, Nkarta, and Allogene; differentiation lies in its focus on the Indian market and proprietary CAR‑NK constructs.